Skip to main content
placeholder image

P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model

Journal Article


Abstract


  • Graft-versus-host disease (GVHD) is a severe inflammatory response arising fromallogeneic haematopoietic stem cell transplantation. Previous studies revealed that antagonism of the P2X7 receptor with Brilliant Blue G (BBG) reduced liver GVHD but did not alter clinical GVHD in a humanised mouse model. Therefore, the present study aimed to trial amodified injection regime using more frequent dosing of BBG to improve outcomes in this model of GVHD. NOD-scid IL2R��null (NSG) mice were injected intraperitoneally (i.p.) with 10 �� 106 human peripheral blood mononuclear cells (hPBMCs) (day 0), then daily with BBG (50 mg/kg) or saline (days 0.10). BBG significantly reduced clinical score, mortality and histological GVHD compared with saline treatment (endpoint). BBG significantly increased proportions of human regulatory T cells (Tregs) and human B cells and reduced serum human interferon-�� compared with saline treatment prior to development of clinical GVHD (day 21). To confirm the therapeutic benefit of P2X7 antagonism, NSG mice were injected i.p. with 10 �� 106 hPBMCs (day 0), then daily with pyridoxalphosphate-6-azophenyl-2���,4���-disulfonic acid (PPADS) (300 mg/kg) or saline (days 0.10). PPADS increased human Treg proportions compared with saline treatment (day 21), but potential clinical benefits were confounded by increased weight loss with this antagonist. To investigate the role of P2X7 antagonism on Treg survival, hPBMCs were cultured in reduced serum conditions to promote cell death. BBG increased proportions of Tregs (and B cells) compared with saline under these conditions. In conclusion, P2X7 antagonism reduces clinical and histological GVHD in a humanised mouse model corresponding to an increase in human Tregs.

Publication Date


  • 2021

Citation


  • Cuthbertson, P., Geraghty, N. J., Adhikary, S. R., Casolin, S., Watson, D., & Sluyter, R. (2021). P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model. Clinical Science, 135(3), 495-513. doi:10.1042/CS20201352

Scopus Eid


  • 2-s2.0-85101526423

Start Page


  • 495

End Page


  • 513

Volume


  • 135

Issue


  • 3

Place Of Publication


Abstract


  • Graft-versus-host disease (GVHD) is a severe inflammatory response arising fromallogeneic haematopoietic stem cell transplantation. Previous studies revealed that antagonism of the P2X7 receptor with Brilliant Blue G (BBG) reduced liver GVHD but did not alter clinical GVHD in a humanised mouse model. Therefore, the present study aimed to trial amodified injection regime using more frequent dosing of BBG to improve outcomes in this model of GVHD. NOD-scid IL2R��null (NSG) mice were injected intraperitoneally (i.p.) with 10 �� 106 human peripheral blood mononuclear cells (hPBMCs) (day 0), then daily with BBG (50 mg/kg) or saline (days 0.10). BBG significantly reduced clinical score, mortality and histological GVHD compared with saline treatment (endpoint). BBG significantly increased proportions of human regulatory T cells (Tregs) and human B cells and reduced serum human interferon-�� compared with saline treatment prior to development of clinical GVHD (day 21). To confirm the therapeutic benefit of P2X7 antagonism, NSG mice were injected i.p. with 10 �� 106 hPBMCs (day 0), then daily with pyridoxalphosphate-6-azophenyl-2���,4���-disulfonic acid (PPADS) (300 mg/kg) or saline (days 0.10). PPADS increased human Treg proportions compared with saline treatment (day 21), but potential clinical benefits were confounded by increased weight loss with this antagonist. To investigate the role of P2X7 antagonism on Treg survival, hPBMCs were cultured in reduced serum conditions to promote cell death. BBG increased proportions of Tregs (and B cells) compared with saline under these conditions. In conclusion, P2X7 antagonism reduces clinical and histological GVHD in a humanised mouse model corresponding to an increase in human Tregs.

Publication Date


  • 2021

Citation


  • Cuthbertson, P., Geraghty, N. J., Adhikary, S. R., Casolin, S., Watson, D., & Sluyter, R. (2021). P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model. Clinical Science, 135(3), 495-513. doi:10.1042/CS20201352

Scopus Eid


  • 2-s2.0-85101526423

Start Page


  • 495

End Page


  • 513

Volume


  • 135

Issue


  • 3

Place Of Publication